Stefan Brew

Great Ormond Street Hospital NHS, London, ENG, United Kingdom

Are you Stefan Brew?

Claim your profile

Publications (6)16.83 Total impact

  • Article: Efficacy and complications of super-selective intra-ophthalmic artery melphalan for the treatment of refractory retinoblastoma.
    [show abstract] [hide abstract]
    ABSTRACT: To report the efficacy of super-selective intra-ophthalmic artery melphalan (IAM) for the treatment of refractory retinoblastoma and any associated complications of this treatment. A prospective case series. Eyes with retinoblastoma that had been treated with systemic chemotherapy or local therapy and had a relapse of their condition. All patients receiving IAM between May 2009 and September 2010 were included in the study. Intra-ophthalmic artery melphalan was offered to patients who had failed to respond adequately to systemic chemotherapy and local treatment where appropriate or because of a new recurrence of retinoblastoma that could not be treated with local therapies. None of the patients were excluded because of central nervous system abnormalities. Patients received 2 treatments of IAM given 4 weeks apart. All patients received an orthoptic assessment 3 weeks after each treatment and an examination under anesthesia (EUA). A third treatment was given if an unsatisfactory response was observed on EUA after 2 treatments. The response of the retinoblastoma tumor(s) and any associated local side effects from the treatment. A total of 15 eyes in 14 patients were treated with IAM during the study period. The mean age at the time of IAM was 31.5 months (median 17.3, range 11.2-150.7 months), and the mean follow-up was 8.7 months (3-16.3 months). Tumor control was achieved in 12 eyes (80%), and 12 eyes (80%) had local side effects that included third cranial nerve palsy in 6 (40%), orbital edema in 3 (20%), permanent retinal detachment in 1 (7%), and vitreous hemorrhage in 4 (27%). Seven eyes (47%) developed significant retinal pigment epithelium changes. Intra-ophthalmic artery melphalan is an effective treatment for retinoblastoma, achieving a high level of remission in refractory tumors. It can be associated with significant local side effects that can result in loss of vision and possible amblyogenesis. Clinicians and parents need to consider the benefits and potential local side effects before embarking on treatment.
    Ophthalmology 12/2011; 119(3):611-6. · 5.45 Impact Factor
  • Article: Angiography and selective microcatheter embolization of a falcine meningioma supplied by the artery of Davidoff and Schechter. Case report.
    [show abstract] [hide abstract]
    ABSTRACT: Angiographic demonstration of the meningeal branch of the posterior cerebral artery, or the artery of Davidoff and Schechter, is extremely rare. The authors describe a case of successful selective catheterization and embolization of a pathologically enlarged artery of Davidoff and Schechter, permitting successful preoperative devascularization of a large falcine meningioma.
    Journal of Neurosurgery 03/2011; 114(3):710-3. · 2.96 Impact Factor
  • Article: Stability of ruptured intracranial aneurysms treated with detachable coils: is delayed follow-up angiography warranted?
    [show abstract] [hide abstract]
    ABSTRACT: The optimal strategy for monitoring the stability of ruptured intracranial aneurysms following coil embolisation is unclear. The value of delayed follow-up angiography in detecting new recurrences or progression of residual lesions visualised on earlier angiographic studies was determined in the light of the increasing use of non-invasive imaging techniques such as time of flight magnetic resonance angiography (TOF-MRA) for the evaluation of intracranial aneurysm occlusion. Ninety-seven patients with 105 ruptured aneurysms treated with detachable coils in 2005 and 2006 were included. The presence of a residual neck or aneurysm was assessed on catheter angiograms performed at 6 months and 2 years using the Raymond criteria (Class I = completely occluded, class II = small residual neck, class III = aneurysm sac filling). At 6-month follow-up, 32% of class I aneurysms progressed to class II and 6% of these aneurysms required re-treatment. A further 2-year angiogram was obtained in 59 patients with 65 aneurysms. Ninety-six per cent of class I, 100% of the class II and class III aneurysms remained unchanged at 2 years compared to 6 months. In our series, most recurrences were apparent at 6-month follow-up. The vast majority of coiled ruptured aneurysms that were class I or II at 6 months remained stable at 2-year follow-up. In the absence of a residual lesion in the early angiographic study, a further delayed catheter angiogram may not be warranted. The use of non-invasive strategies such as TOF-MRA should be considered.
    British Journal of Neurosurgery 08/2010; 24(4):405-9. · 0.88 Impact Factor
  • Article: Outcome in poor grade subarachnoid hemorrhage patients treated with acute endovascular coiling of aneurysms and aggressive intensive care.
    [show abstract] [hide abstract]
    ABSTRACT: Patients with poor grade (World Federation of Neurosurgeons (WFNS) Grades 4 and 5) subarachnoid hemorrhage (SAH) were historically considered to have a poor neurological outcome and therefore not traditionally offered aggressive treatment. In recent years there has been increasing evidence that early aggressive treatment of this patient group can result in a good outcome. Aim of this study is to identify the outcome of patients with WFNS Grade-4 and -5 SAH treated acutely with endovascular detachable coil embolization (DCE) and aggressive neurocritical care within our institution. We retrospectively reviewed the records of patients with SAH WFNS Grades 4 and 5 treated with DCE within 7 days of admission between 1st January 2004 and 1st January 2008. Data collected included age, sex, grade SAH, position/number of Aneurysms, coiling complications, time spent on the neurosurgical critical care unit (NCCU), and 6-month outcome assessed by Glasgow outcome scale (GOS). GOS was dichotomized into good outcome (good recovery/moderate disability) and poor outcome (severe disability, vegetative, dead). A total of 193 acute SAH patients were admitted and treated within this time period, of these, 47 patients were classified as poor grade and included: 70% were female and 30% were male. The mean age was 56 years (33-88 years range). A total of 56 aneurysms were noted at angiography, 52 aneurysms were coiled. Complications of SAH Vasospasm was noted in 18 patients (38%), cerebral infarction in 13 patients (28%), seizures in 7 patients (15%), hydrocephalus in 25 patients (53%). Complications of DCE occurred in 2 patients (4% of total) these were an aneurysmal rupture and a peri-procedure thrombosis. Incomplete coiling occurred in another 5 patients (10.6% of total) due to technical difficulties. The median length of stay on the NCCU was 12 days (1-52 days range). Of the 47 poor grade patients coiled, 25 (53%) had a good outcome (good recovery/moderate disability) and 22 (47%) had a poor outcome (severe disability, vegetative, dead) by the time of the 6-month follow-up. Potentially, more than half the patients with WFNS Grade-4 and -5 SAH who are treated aggressively with coil embolization in association with supportive neurocritical care can achieve a good quality neurological outcome. However, it should be anticipated that these patients will spend a significant period of time in neurocritical care.
    Neurocritical Care 05/2010; 14(3):341-7. · 2.47 Impact Factor
  • Article: Repair of sinus venosus defect in a patient with untreated vein of Galen aneurysmal malformation.
    [show abstract] [hide abstract]
    ABSTRACT: The vein of Galen aneurysmal malformation (VGAM) is a rare cerebral arteriovenous shunt, which may be associated with a congenital cardiac defect. Embolisation of the VGAM may be undertaken in the neonatal period if necessary, but is safer in infancy. Recent advances in neuroradiology have changed the prognosis for this group with many patients achieving survival with normal development. This case report describes a patient with a sinus venosus defect (SVD) and a VGAM and considers both the optimal timing of treatment of the two malformations and the conduct of anaesthesia for open repair of the SVD in the presence of an untreated VGAM.
    Pediatric Anesthesia 07/2008; 18(6):548-53. · 2.10 Impact Factor
  • Article: Multislice spiral computed tomography for pediatric intracranial vascular pathophysiologies.
    [show abstract] [hide abstract]
    ABSTRACT: Spiral computed tomography (SCT) and, more recently, multislice SCT (MSCT) angiography have established roles in studying subarachnoid hemorrhage (SAH). Potential advantages in MSCT angiography include rapid acquisition, ready availability, ease of monitoring, high spatial resolution, some temporal resolution, and relative freedom from artifacts. The authors assert that these attributes make MSCT angiography the initial imaging method of choice in the assessment of not just SAH but all intracranial vascular pathophysiologies, particularly in children. The installation of a MSCT unit sparked the authors' interest in using MSCT angiography and MSCT venography in cases in which they would have formerly performed magnetic resonance (MR) angiography, MR venography, or catheter angiography as an initial investigational method. They retrospectively evaluated seven cases in which they had used the former imaging techniques to study intracranial vascular pathophysiologies. All scans were obtained on a Siemens Sensation 16-slice scanner, and postprocessing was performed on a Leonardo Workstation. Multislice spiral CT consistently provided useful vascular imaging of a wide variety of intracranial vascular pathophysiologies and an alternative imaging modality in patients considered to be too unstable for more time-consuming investigations. Multislice spiral CT offers advantages over MR imaging in the assessment of intracranial vascular pathophysiologies and frequently allows complete avoidance or deferral of catheter angiography.
    Journal of Neurosurgery 10/2007; 107(3 Suppl):203-8. · 2.96 Impact Factor